EPS CAGR: -50.57% (5Y, annualized)

EPS CAGR uses the stored diluted-earnings history where available.

Over longer horizons, EPS CAGR averages -50.57% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. EPS (Earnings Per Share) CAGR measures how the company's earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.

SABS EPS CAGR Chart

SAB Biotherapeutics, Inc. (SABS)

SABS Quarterly EPS Growth (YoY)

EPS growth vs the same fiscal quarter in the prior fiscal year, last 15 comparable quarters.

EPS

SABS Quarterly EPS

$-0.28

Reported quarterly earnings per share; no daily interpolation. Q2 FY2026 (2026-06-30): $-0.28.

-103.31% over 10Y

SABS P/E Ratio

Full P/E Ratio page

P/E Ratio

SABS P/E Ratio Chart

N/A

FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T21:33:53.043Z. Historical observations retain their original dates. Historical series through 2022-03-29.

SABS EPS CAGR History

Year	Start EPS	End EPS	Change	% Change
2025	−$3.68	$0.22	+$3.9	N/A
2024	−$7.64	−$3.68	+$3.96	N/A
2023	−$4.31	−$7.64	−$3.33	N/A
2022	−$6.3	−$4.31	+$1.99	N/A
2021	$7.45	−$6.3	−$13.75	-184.56%
2020	−$0.22	$7.45	+$7.67	N/A

Quarterly EPS: QoQ & YoY

Period	Period End	Value	QoQ Growth	YoY Growth
Q2 FY2026	2026-06-30	$-0.28	+20.0%	+74.3%
Q1 FY2026	2026-03-31	$-0.35	N/A	+37.5%
Q4 FY2025	2025-12-31	$-0.06	N/A	+95.1%
Q3 FY2025	2025-09-30	$4.26	N/A	N/A
Q2 FY2025	2025-06-30	$-1.09	-94.6%	-38.0%
Q1 FY2025	2025-03-31	$-0.56	+54.5%	-3.7%